Cilostazol: The "Poor Man's" Replacement of Drug Eluting Stents and Balloons?
In the present multi-center randomized controlled STOP-IC trial Iida and colleagues1 investigate the effect of cilostazol, which is chemically a quinolinone-derivative, on the procedural and clinical outcome of femoro-popliteal interventions. The major finding of the study is a significant 59 percent relative reduction of the 1-year restenosis rate as determined by angiography (20% in the cilostazol group versus 49% in the placebo group, respectively). It must be considered, however, that angiographic follow-up data was available in 80 % of the cohort at 12 months. In addition, despite comparable hemodynamic improvement in both study cohorts at 1 year - secondary patency rates and ankle-brachial indices (ABI) were almost identical due to a significantly higher re-intervention (TLR) rate in the control cohort - patients had significantly improved clinical symptoms in the cilostazol cohort.
- Received May 3, 2013.
- Accepted May 6, 2013.